Stay updated on Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The study's Locations section was updated to reflect 39 participating sites, replacing the previous larger roster and changing the geographic mix of sites.
    Difference
    3%
    Check dated 2026-04-28T21:42:51.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    Updated the displayed revision/version from **v3.5.0** to **v3.5.2**.
    Difference
    0.0%
    Check dated 2026-04-21T15:58:26.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    30 days ago
    Change Detected
    Summary
    The study record history was updated with new entries on 2026-03-27 and 2026-03-30. Earlier updates from 2026-03-06 and 2026-03-09 were removed.
    Difference
    0.1%
    Check dated 2026-03-31T00:37:52.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    Revision tag updated to v3.5.0 and the previous tag v3.4.3 was removed.
    Difference
    0.0%
    Check dated 2026-03-23T18:10:01.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    The study locations list was updated to reflect 56 sites, with additions across multiple countries and removals of several previously listed sites.
    Difference
    3%
    Check dated 2026-03-16T06:36:10.000Z thumbnail image
  7. Check
    52 days ago
    Change Detected
    Summary
    Site revision updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-09T01:13:26.000Z thumbnail image

Stay in the know with updates to Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.